wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38198934-173E99F3-3DF4-48AB-B803-A0E16ADC5B8E
Q38198934-173E99F3-3DF4-48AB-B803-A0E16ADC5B8E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38198934-173E99F3-3DF4-48AB-B803-A0E16ADC5B8E
Novel bone-targeting agents in prostate cancer.
P2860
Q38198934-173E99F3-3DF4-48AB-B803-A0E16ADC5B8E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38198934-173E99F3-3DF4-48AB-B803-A0E16ADC5B8E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6e80ca897b5b44261d6f9c5e1e51eac2b1c60bd3
P2860
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.